Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:03 2024-05-31 EDT			5-day change	1st Jan Change
8.885 ^USD	-1.28%		-11.24%	+9.29%

06-01	Transcript : Iovance Biotherapeutics, Inc. - Special Call
05-13	Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained	MT

Iovance Biotherapeutics, Inc. Appoints Igor Bilinsky as Chief Operating Officer

March 15, 2021 at 04:01 pm

Iovance Biotherapeutics, Inc. announced the appointment of Igor Bilinsky, Ph.D., as Chief Operating Officer, effective March 15, 2021. Dr. Bilinsky brings more than 20 years of biotechnology industry experience as a senior executive and consultant, including public companies.

Latest news about Iovance Biotherapeutics, Inc.

Transcript : Iovance Biotherapeutics, Inc. - Special Call	05-31
Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained	05-13	MT
Truist Adjusts Iovance Biotherapeutics' Price Target to $25 From $26, Keeps Buy Rating	05-13	MT
Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says	05-10	MT
Iovance Biotherapeutics Shares Fall After Q1 Revenue Misses Estimates	05-10	MT
Iovance Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Iovance Biotherapeutics Q1 Loss Narrows -- Shares Higher After Hours	05-09	MT
Transcript : Iovance Biotherapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Posts Q1 Revenue $715,000	05-09	MT
General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election	03-29	CI
Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating	03-14	MT
Transcript : Iovance Biotherapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:45 AM	03-12
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday	03-04	MT
Iovance Biotherapeutics Says FDA Lifts Partial Clinical Hold on Lung Cancer Study	03-04	MT
Iovance Biotherapeutics Syas FDA Lifts Partial Clinical Hold on LN-145	03-04	DJ
Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer	03-04	CI
Wells Fargo Adjusts Price Target on Iovance Biotherapeutics to $25 From $22, Maintains Overweight Rating	03-01	MT
Barclays Raises Price Target on Iovance Biotherapeutics to $22 From $18, Maintains Overweight Rating	02-29	MT
Iovance Biotherapeutics Q4 Loss Narrows, Posts Revenue	02-29	MT
Transcript : Iovance Biotherapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	02-28
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Reports Q4 Revenue $482,000	02-28	MT
Iovance Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-28	CI
Iovance Biotherapeutics Insider Bought Shares Worth $45,750,000, According to a Recent SEC Filing	02-21	MT
Iovance Biotherapeutics Insider Bought Shares Worth $292,800, According to a Recent SEC Filing	02-21	MT
Iovance Biotherapeutics Insider Bought Shares Worth $2,287,500, According to a Recent SEC Filing	02-21	MT

Chart Iovance Biotherapeutics, Inc.

Duration

Period

More charts

Company Profile

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.

Sector

Biotechnology & Medical Research

Calendar

2024-06-06 - Jefferies Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Iovance Biotherapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.88 USD

Average target price

25.92 USD

Spread / Average Target

+191.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
IOVANCE BIOTHERAPEUTICS, INC.	+9.29%	2.48B
EXACT SCIENCES CORPORATION	-38.56%	8.39B
GUARDANT HEALTH, INC.	+0.18%	3.32B
BGI GENOMICS CO., LTD.	-18.21%	2.06B
VERACYTE, INC.	-24.57%	1.59B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+32.37%	1.15B
SEEGENE, INC.	-7.64%	704M
CAREDX, INC	+8.42%	678M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.59%	508M
CURIOX BIOSYSTEMS CO., LTD	-6.56%	273M

Bio Diagnostics & Testing